[ad_1] While debate rages on about when the Federal Reserve might start cutting interest rates, biotech industry analysts are making the case that the argument for stocks in the sector is growing. The central bank has held rates steady since last July as it patiently waits for more signs that inflation is cooling. But a…
[ad_1] Jonathan Raa | Nurphoto | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday. But J&J’s drug…
[ad_1] Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services building in Washington, D.C., on Oct. 6, 2022. Anna Moneymaker | Getty Images A federal judge on Friday rejected AstraZeneca‘s legal challenge to Medicare’s new power to negotiate the prices of certain costly prescription drugs…
[ad_1] There’s been a lot of chatter about the mental health crisis since the Covid-19 pandemic. Overall, 12 mental health disorders affect 970 million people around the world — or one in eight people, according to the Institute for Health Metrics and Evaluation’s Global Burden of Disease. That can mean anything from anxiety and depression…
[ad_1] Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday dismissed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations that…
[ad_1] Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024. Bill Clark | Cq-roll Call, Inc. | Getty Images Senators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb…
[ad_1] Traders work on the floor at the New York Stock Exchange on Feb. 1, 2024. Brendan McDermid | Reuters Here’s how big of a surprise corporate profits have been this earnings season: The fourth quarter is now shaping up to be the best of 2023. Despite ongoing macroeconomic concerns that have hampered demand and…
[ad_1] Clorox – The consumer products giant saw a huge earnings beat. It’s also rebounding from last year’s cyberattack. “Things are back online, and there’s tremendous demand for their product,” Jim said Friday’s Morning Meeting rapid fire. Tesla – The EV leader issued a recall for 2.2 million cars over a warning light issue. Remember,…
[ad_1] Bristol Myers Squibb reported quarterly earnings and revenue that topped expectations on Friday as its portfolio of new drugs posted strong sales growth. Here’s what the company reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share:…
[ad_1] Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com. Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few…
